Overall rank by patents
#28,621
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
ECI Pharmaceuticals, Llc
USPTO PatentsView assignee record - 9 granted patents across 3 technology areas, active 2019–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
9
Total patents granted
3
CPC technology areas
27.7
Avg claims per patent
+700%
5-year filing velocity
The verdict
ECI holds 9 US patents across 3 technology areas, rank #28,621 of 50,000 tracked assignees.
- #28,621
- of 50,000 US assignees by volume
- Top 59%
- by Innovation Score (32.4/100)
- 27.7
- avg claims per patent
- +700%
- filing velocity, last 5 yrs
Portfolio overview
ECI Pharmaceuticals, Llc has been granted 9 US utility patents between 2019 and 2022, placing ECI Pharmaceuticals, Llc at rank #28,621 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 27.7 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, ECI Pharmaceuticals, Llc is one of the more focused assignees in the PatentsView dataset. By volume, ECI sits between Easyhome Organization Manufacturing Inc. (9 patents, rank #28,617) and Edgewise Therapeutics, Inc. (9 patents, rank #28,625) - the closest US assignees by grant volume. The composite Innovation Score of 32.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 8 grants, compared with 1 in the 2015–2019 window, a +700% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. ECI Pharmaceuticals, Llc's 27.7 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ECI Pharmaceuticals, Llc against peers pursuing similar technology classes.
Who files at ECI's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Easyhome Organiza…
EASYHOME ORGANIZATION MANUFACTURING INC.
9 patents
- Ebara Internation…
EBARA International Corporation
9 patents
- ECC TEC MSJ Incor…
ECC TEC MSJ INCORPORATED
9 patents
- Echowell
ECHOWELL ELECTRONIC CO., LTD
9 patents
- Ecole Centrale DE…
ECOLE CENTRALE DE NANTES
9 patents
- Ecole Nationale S…
ECOLE NATIONALE SUPERIEURE D'ARTS ET METIERS (ENSAM)
9 patents
- Economic Alchemy
ECONOMIC ALCHEMY INC.
9 patents
- Edgewise Therapeu…
EDGEWISE THERAPEUTICS, INC.
9 patents
- ECI Pharmaceutica… ◀
ECI PHARMACEUTICALS, LLC
9 patents
What this shows ECI holds 9 patents at rank #28,621, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near ECI
By rank, the assignees closest to #28,621 in granted patent volume.
- Easyhome Organization Manufacturing Inc. #28,617 · 9 patents
- Ebara International Corporation #28,618 · 9 patents
- ECC TEC MSJ Incorporated #28,619 · 9 patents
- Echowell Electronic Co., Ltd #28,620 · 9 patents
- Ecole Centrale DE Nantes #28,622 · 9 patents
- Ecole Nationale Superieure D'arts ET Metiers (ensam) #28,623 · 9 patents
- Economic Alchemy Inc. #28,624 · 9 patents
- Edgewise Therapeutics, Inc. #28,625 · 9 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in ECI's primary technology class.
- The Regents Of The University Of California 1,779 in class
- L'oreal 1,250 in class
- Novartis Ag 988 in class
- The Procter & Gamble Company 985 in class
- The Board Of Regents Of The University Of Texas System 950 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 813 in class
- The Trustees Of The University Of Pennsylvania 768 in class
- Merck Sharp & Dohme Llc 760 in class
ECI's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
32 Top 59% higher than 41% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 11.1% |
| 2020 | 2 | 22.2% |
| 2021 | 3 | 33.3% |
| 2022 | 3 | 33.3% |
Which technologies does ECI Pharmaceuticals, Llc patent most?
Top 3 of 3 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Velocity Accelerating
Frequently Asked Questions
How many patents does ECI Pharmaceuticals, Llc hold?
ECI Pharmaceuticals, Llc holds 9 US granted patents filed between 2019 and 2022, spanning 3 technology areas.
What is ECI Pharmaceuticals, Llc's Innovation Score?
ECI Pharmaceuticals, Llc has an Innovation Score of 32.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does ECI Pharmaceuticals, Llc focus on?
ECI Pharmaceuticals, Llc's top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 9 patents. The company has filed patents in 3 CPC subclasses total.
Is ECI Pharmaceuticals, Llc's patent filing rate increasing or decreasing?
ECI Pharmaceuticals, Llc's recent filing velocity is +700% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for ECI Pharmaceuticals, Llc's patents?
ECI Pharmaceuticals, Llc's patents average 27.7 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the ECI Pharmaceuticals, Llc patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
ECI's 9 grants land it in the top 59% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - ECI ranks #28,621 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.